Siren Biotechnology Receives $8M Grant from CIRM to Support Clinical Development of SRN-101 for High-Grade Glioma
Siren Biotechnology has been awarded an $8 million non-dilutive grant by the California Institute for Regenerative Medicine (CIRM) to support clinical development of its lead investigational therapy, SRN-101. The funding will help advance a Phase 1/2 trial in adult patients with recurrent high-grade glioma following FDA clearance of Siren's IND application.